Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO
Filter by Topic
ASCO 2014 Highlights
ASCO 2014 – Colorectal and Head & Neck Cancer
ASCO 2014 – Immuno-Oncology
ASCO 2014 – Lung Cancer
ASCO 2015 - Lung Cancer
ASCO 2015 Highlights
ASCO 2016 – Lung Cancer
ASCO 2017 – Multiple Myeloma
ASCO 2018 Insights
ASCO 2019
ASCO 2020 Cholangiocarcinoma
ASCO Breast Cancer Symposium
ASCO Quality Care Symposium
ASCO’s 1st Quality Care Symposium
Daratumumab, Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in RRMM: Efficacy and Safety Update (CASTOR)
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
Researchers from the CASTOR trial provided an update on the efficacy and safety of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Trends in Survival and Costs Among US Patients with Multiple Myeloma
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
This study examined the trends in survival and healthcare costs of US patients with multiple myeloma from 2006 to 2014.
Read Article
Comparative Efficacy of MM Therapies for Treatment of First Relapse: A Systematic Literature Review and Network Meta-Analysis
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
A systematic literature review and network meta-analysis were conducted to determine the comparative efficacy of multiple myeloma (MM) therapies for treating first relapse.
Read Article
Racial Differences in Abnormalities by FISH in Minorities with Multiple Myeloma: A Single-Center Experience
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
This study provides a closer look at the racial differences in fluorescence in situ hybridization (FISH) abnormalities in minorities with multiple myeloma.
Read Article
Cost-Effectiveness of Carfilzomib, Ixazomib, Elotuzumab, or Daratumumab with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
The combination of daratumumab plus lenalidomide and dexamethasone is associated with the greatest progression-free survival life-years and quality-adjusted life-years versus combinations including carfilzomib, ixazomib, and elotuzumab with relapsed/refractory multiple myeloma (RRMM).
Read Article
Targeting the VEGF Axis in Advanced NSCLC
By
Benjamin P. Levy, MD
ASCO
,
ASCO 2016 – Lung Cancer
Videos
Benjamin P. Levy, MD, reviews current and emerging roles for agents that target the VEGF axis in advanced non–small-cell lung cancer and expresses his belief that a lot of work needs to be done to define the optimal space for these drugs.
Read Article
The Future of Immuno-oncology in Advanced Lung Cancer
By
Benjamin P. Levy, MD
ASCO
,
ASCO 2016 – Lung Cancer
Videos
Benjamin P. Levy, MD, discusses the value in leveraging clinical trials to determine the potential of utilizing checkpoint inhibitors as single agent first line therapies and in combination with chemotherapy as a second line strategy.
Read Article
Treating Patients with Acquired TKI Resistance
By
Benjamin P. Levy, MD
ASCO
,
ASCO 2016 – Lung Cancer
Videos
Benjamin P. Levy, MD, provides an overview of evolving strategies to manage patients with acquired TKI resistance in advanced non–small-cell lung cancer with a focus on identifying and treating t790m.
Read Article
Utilizing Chemotherapy to Treat Lung Cancer
By
Benjamin P. Levy, MD
ASCO
,
ASCO 2016 – Lung Cancer
Videos
Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer.
Read Article
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Page 3 of 19
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma